Literature DB >> 8040297

X inactivation and immunocompetence in female carriers of the X-linked hyper-IgM syndrome.

T J Kipps.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8040297      PMCID： PMC295103          DOI： 10.1172/JCI117355

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  8 in total

1.  Analysis of X-chromosome inactivation in X-linked immunodeficiency with hyper-IgM (HIGM1): evidence for involvement of different hematopoietic cell lineages.

Authors:  L D Notarangelo; O Parolini; A Albertini; M Duse; E Mazzolari; A Plebani; G Camerino; A G Ugazio
Journal:  Hum Genet       Date:  1991-12       Impact factor: 4.132

Review 2.  How B and T cells talk to each other.

Authors:  E A Clark; J A Ledbetter
Journal:  Nature       Date:  1994-02-03       Impact factor: 49.962

Review 3.  Immunodeficiency with hyper-IgM (HIM).

Authors:  L D Notarangelo; M Duse; A G Ugazio
Journal:  Immunodefic Rev       Date:  1992

4.  Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40.

Authors:  F H Durie; R A Fava; T M Foy; A Aruffo; J A Ledbetter; R J Noelle
Journal:  Science       Date:  1993-09-03       Impact factor: 47.728

5.  CD40 preferentially costimulates activation of CD4+ T lymphocytes.

Authors:  M Cayabyab; J H Phillips; L L Lanier
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

6.  CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM.

Authors:  J P DiSanto; J Y Bonnefoy; J F Gauchat; A Fischer; G de Saint Basile
Journal:  Nature       Date:  1993-02-11       Impact factor: 49.962

Review 7.  CD40 ligand and its role in X-linked hyper-IgM syndrome.

Authors:  R E Callard; R J Armitage; W C Fanslow; M K Spriggs
Journal:  Immunol Today       Date:  1993-11

8.  The random inactivation of the X chromosome carrying the defective gene responsible for X-linked hyper IgM syndrome (X-HIM) in female carriers of HIGM1.

Authors:  D Hollenbaugh; L H Wu; H D Ochs; S Nonoyama; L S Grosmaire; J A Ledbetter; R J Noelle; H Hill; A Aruffo
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.